Introduction
============

The total synthesis of complex natural product small molecules invites the examination of various methodologies in a complicated system, which at times reveals current limitations and inspires new advances.[@cit1] Importantly, total synthesis could also provide valuable analogs to explore the structure--activity relationships of targeted chemotypes.[@cit2] We have been interested in using rearrangement reactions that lead to dramatic changes in molecular skeletons to develop novel and efficient synthetic routes towards various biologically active natural products.[@cit3] Herein, we describe a concise and collective synthesis[@cit4] of *iboga* alkaloids and vinblastine which further substantiates these concepts.

The *iboga* alkaloid family of natural products comprises over 60 members of monoterpene indoles that share a common pentacyclic skeleton of ibogamine ([Fig. 1](#fig1){ref-type="fig"}).[@cit5] Among the various neurological activities of ibogamine (**1**) and ibogaine (**2**), the most exciting one is their capability to attenuate the addiction to a number of drugs, although the molecular mechanism of action remains largely elusive.[@cit6] Ibogaine, as the most abundant alkaloid in the root bark of the shrub *Tabernanthe iboga*, has even been studied in a clinical setting.[@cit6] Interestingly, both enantiomers of ibogamine are not only active in reducing the self-administration of cocaine and morphine in rats but are also devoid of tremorigenic activity---a side effect exhibited by ibogaine, which hence deserves further investigation.[@cit7] Catharanthine (**3**) and its derivative dihydrocatharanthine (**4**) have recently been identified as among the most potent TRPM8 antagonists and modulate cold-induced pain signals as well as mammalian thermoregulation.[@cit8] More importantly, the conversion of catharanthine to the potent anti-cancer drug vinblastine (**5**) *via* a one-pot procedure has boosted the value of this iboga alkaloid, and its derivatives have led to vinblastine analogs revealing insightful structure--activity relationships.[@cit9]

![Representative *iboga* alkaloids and vinblastine.](c6sc00932h-f1){#fig1}

Despite the variety of synthetic approaches towards different *iboga* alkaloids that have been reported, the enantioselective total syntheses remain relatively sparse.[@cit10]--[@cit13] Since Trost\'s group published the elegant synthesis of enantioenriched ibogamine in 1978,[@cit11] the preparation of chiral isoquinuclidine fragments followed by the construction of a C2--C16 bond in the late stages (catharanthine numbering, throughout) has become the focus of asymmetric synthesis studies.[@cit12] The only two exceptions are the efficient syntheses of (--)-ibogamine and (--)-catharanthine by White\'s group and Oguri\'s group respectively, both employing the asymmetric Diels--Alder reaction.[@cit13] An alternative approach to prepare such a privileged skeleton, especially in an enantioselective manner, would be a valuable addition to current synthetic endeavours and more importantly, would enable flexible structural changes of this chemotype.

Results and discussion
======================

While seeking a unified strategy to access *iboga* alkaloids with and without the methoxycarbonyl group at C16, we envisioned two late-stage intermediates **6a** and **6b** ([Fig. 2](#fig2){ref-type="fig"}). The C20 carbonyl group of **6** could be a versatile handle for the preparation of bioactive natural products and small-molecule probes. Inspired by the transannular cyclization accomplished by Kutney and co-workers,[@cit10b] as well as recent advances in the fragmentation of the C16--C21 bond,[@cit14] we decided to explore the \[1,2\]-Stevens rearrangement of ammonium ylide **7** to construct the C16--C21 bond and give the structurally compact product **6**.[@cit15] Given that zwitterion **7** could be generated from the quaternary ammonium cation **8** upon treatment with base due to the enhanced acidity at C21, **6** would therefore be accessible from **8** in one step. This key precursor **8** could be prepared by intramolecular alkylation of the tertiary amine **9**, for which we hypothesized that the recently developed gold-catalyzed conversion of terminal alkynes to α-chloromethyl ketones could find application.[@cit16] Thus, the tertiary amine **10** became the precursor for **9**, which could be traced back to the known amide **11***via* propargylation and reduction.[@cit17],[@cit18]

![Retrosynthetic analysis of *iboga* alkaloids based on the \[1,2\]-Stevens rearrangement reaction.](c6sc00932h-f2){#fig2}

We commenced our studies with the chiral amide **11a**, which was prepared from tryptamine in 3 steps *via* the organocatalytic Pictet--Spengler reaction reported by Jacobsen\'s group ([Scheme 1](#sch1){ref-type="fig"}).[@cit17] The introduction of the propargyl group was achieved with the protection of the nitrogen atom, and the following deprotection afforded a pair of readily separable diastereomers, where the desired stereoisomer **13a** was isolated as the major product in 52% yield over 3 steps. The subsequent reduction of **13a** by LiAlH~4~ produced the tertiary amine **10a** smoothly in 85% yield. We ultimately developed a one-pot procedure that converted **10a** to the quaternary ammonium compound **8a** in good yield (see the ESI[†](#fn1){ref-type="fn"} for the determination of the counteranion).

![Preparation of the quaternary ammonium compound **8a**. Reagents and conditions: (a) Boc~2~O (3.0 equiv.), TEA (1.1 equiv.), DMAP (0.2 equiv.), DCM, RT, 14 h, 89%; (b) LDA (1.2 equiv.), propargyl bromide **12** (2.5 equiv.), --78 °C to RT, 2 h, THF; (c) TFA (5.0 equiv.), DCM, RT, 16 h; 58% over two steps; (d) LiAlH~4~ (3.0 equiv.), THF, 80 °C, 1 h, 85%; (e) PPh~3~AuNTf~2~ (5 mol%), **14** (2.0 equiv.), MsOH (1.3 equiv.), TFA (1.1 equiv.), AgOTf (2 mol%), DCE, RT, 6 h; then NaHCO~3~ (sat.), AgOTf (1.0 equiv.), RT, 73%.](c6sc00932h-s1){#sch1}

The extensive optimization of this gold-catalyzed reaction followed by intramolecular alkylation was carried out using racemic **10a** ([Table 1](#tab1){ref-type="table"} and S1[†](#fn1){ref-type="fn"}). The basicity of the tertiary amine **10a** is detrimental to the cationic gold catalysis and needs to be neutralized with the addition of another equivalent of acid.[@cit16b],[@cit19] Using a 10 mol% (Ph~3~P)AuNTf~2~ catalyst and 2 equiv. of MsOH additive, we examined a variety of oxidants and identified 2-bromopyridine *N*-oxide **14** as the optimal one (Table S1[†](#fn1){ref-type="fn"}). The formation of intermediate **15** was supported by LCMS analysis, and the intermediate then underwent facile cyclization upon the treatment of the reaction mixture with a saturated aqueous solution of sodium bicarbonate. The end product **8a** was obtained in 47% yield with the recovery of 39% starting material **10a** ([Table 1](#tab1){ref-type="table"}, entry 1). Inspired by the screening of the acid additives to improve the conversion in similar transformations,[@cit20] we discovered that complete consumption of **10a** was achieved in 20 h at room temperature with 1.3 equiv. MsOH and 1.1 equiv. TFA as the acid additives to afford **8a** in 63% isolated yield (entry 2). The addition of 3 mol% AgOTf significantly accelerated the reaction,[@cit21] which gave **8a** in 69% yield on an even larger scale (200 mg scale, entry 3). We intentionally lowered the gold catalyst loading to 5 mol% for the gram scale reaction and found that the first step went to completion in 8 h at room temperature but **8a** was isolated in only 51% yield after workup (entry 4). The conditions for the gram scale reaction were further improved by discovering that the addition of 1 equiv. AgOTf effectively promoted the cyclization step, which eventually afforded **8a** in 74% isolated yield (entry 5).

###### Gold-catalyzed synthesis of **8a**: selected optimization[^*a*^](#tab1fna){ref-type="fn"}

  ![](c6sc00932h-u1.jpg){#ugr1}                                            
  ------------------------------- --------------------------------- ------ -------------------------------------------
  1                               2.1 equiv. MsOH                   24 h   47%[^*c*^](#tab1fnc){ref-type="table-fn"}
  2                               1.3 equiv. MsOH, 1.1 equiv. TFA   20 h   63%
  3                               1.3 equiv. MsOH, 1.1 equiv. TFA   6 h    69%[^*d*^](#tab1fnd){ref-type="table-fn"}
  4                               1.3 equiv. MsOH, 1.1 equiv. TFA   8 h    51%[^*e*^](#tab1fne){ref-type="table-fn"}
  5                               1.3 equiv. MsOH, 1.1 equiv. TFA   8 h    74%[^*f*^](#tab1fnf){ref-type="table-fn"}

^*a*^\[**10a**\] = 0.1 M (0.12 mmol).

^*b*^Isolated yield after flash chromatography.

^*c*^39% starting material **10a** was recovered.

^*d*^200 mg scale reaction, 3% AgOTf was added as an additive.

^*e*^1 g scale reaction, 5% PPh~3~AuNTf~2~, 2% AgOTf as an additive.

^*f*^3 g scale reaction, 5% PPh~3~AuNTf~2~, 2% AgOTf as an additive, 1 equiv. AgOTf was added with NaHCO~3~ (s, aq.) to facilitate the cyclization.

With abundant **8a** in hand, we proceeded to test the Stevens rearrangement. Initial efforts in base, solvent and temperature screening proved unfruitful, leading to either starting material recovery or decomposition (Table S2[†](#fn1){ref-type="fn"}). Inspired by the development of organocatalytic sigmatropic reactions,[@cit22] we shifted our focus to exploiting a novel Stevens rearrangement through the intermediacy of an enamine.[@cit23] By examining a variety of amines (Table S3[†](#fn1){ref-type="fn"}), we identified that 5 equiv. of piperidine **16** could promote the desired transformation in methanol even if the isolated yield of **6a** was only 11% after heating at 170 °C for 8 h in a sealed tube ([Table 2](#tab2){ref-type="table"}, entry 1).[@cit24] We therefore turned to microwave technology and found that it was more effective than conventional thermal conditions (entry 2).[@cit25] Through a series of optimization procedures including the amount of **16** (entry 3), solvent (entry 4), concentration and heating sequence (entry 5), the *iboga* alkaloid framework **6a** was eventually obtained from **8a** in 50--60% isolated yield (over 90% yield based on starting material recovery). Furthermore, when *N*-methylmorpholine was employed in place of piperidine **16** under the optimized reaction conditions, we did not observe the formation of **6a** and the starting material **8a** was recovered in 88% yield, thus suggesting that the formal Stevens rearrangement was not base mediated. To the best of our knowledge, this transformation represents the first example of Stevens rearrangement through secondary amine catalysis.

###### Rearrangement of **8a** to **6a**: selected optimization

  ![](c6sc00932h-u2.jpg){#ugr2}                                                                                     
  ------------------------------- -------------------------------------------------------------------------- ------ -------------------------------------------------------------------------------------------------------------------------------
  1                               5 equiv. **16**, MeOH, 170 °C, 8 h[^*d*^](#tab2fnd){ref-type="table-fn"}   46%    13%
  2                               5 equiv. **16**, MeOH, 120 °C (mW), 12 h                                   N.D.   21%
  3                               0.4 equiv. **16**, MeOH, 120 °C (mW), 8 h                                  N.D.   32%[^*e*^](#tab2fne){ref-type="table-fn"}
  4                               0.4 equiv. **16**, HFIP, 150 °C (mW), 3 h                                  45%    47%[^*e*^](#tab2fne){ref-type="table-fn"} ^,^[^*f*^](#tab2fnf){ref-type="table-fn"}
  5                               0.4 equiv. **16**, HFIP, 150 °C (mW), 3 h                                  58%    56%[^*e*^](#tab2fne){ref-type="table-fn"} ^,^[^*f*^](#tab2fnf){ref-type="table-fn"} ^,^[^*g*^](#tab2fng){ref-type="table-fn"}

^*a*^\[**8a**\] = 0.1 M (0.075 mmol).

^*b*^Conversion was calculated based on the recovery of **8a**.

^*c*^Isolated yield after column chromatography.

^*d*^The reaction was carried out in a sealed tube.

^*e*^The reaction vial was pretreated by *N*,*O*-bis(trimethylsilyl)acetamide.

^*f*^\[**8a**\] = 0.5 M (1 mmol).

^*g*^The heating sequence was composed of 12 cycles with each cycle including irradiation at 150 °C for 15 min and at 50 °C for 15 min.

The stage was set for the late-stage functional group manipulations of **6a** ([Scheme 2](#sch2){ref-type="fig"}). First, the addition of an organocerium reagent, prepared from ethylmagnesium bromide, to the ketone afforded **17** as a single diastereomer, effectively completing the formal synthesis of (+)-catharanthine (**3**).[@cit10d],[@cit12c] The Wittig reaction was then employed to convert **6a** to olefin **18**, where the *Z* configuration of the trisubstituted olefin was assigned by a NOESY experiment (see ESI[†](#fn1){ref-type="fn"} for details). Hydrogenation of alkene **18** using activated Pd/C as the catalyst afforded epiibogamine **19** in 97% yield.[@cit26] The high stereoselectivity could be attributed to the preferential addition of H~2~ to the less hindered side of the molecule. Therefore we turned to the radical-based hydrogenation of electron-neutral alkenes initiated by hydrogen atom transfer.[@cit27] While manganese and cobalt-based catalyst precursors also produced **19** as the predominant product (Table S4[†](#fn1){ref-type="fn"}), we were delighted to find that Fe(acac)~3~, the precatalyst reported by Baran and co-workers for reductive alkene coupling,[@cit28] afforded separable **19** and (+)-ibogamine **1** in 34% and 26% yields, respectively. The key intermediate **6a** could be expediently decorated to other interesting derivatives with an *iboga* alkaloid skeleton. For instance, the reductive cyanation of ketone **6a** with tosylmethylisocyanide produced a pair of separable diastereomers **20** and **21** in 25% and 54% yields, respectively.[@cit29] The structures of racemic **19** and **20** were determined unambiguously by X-ray crystallography,[@cit30] while the analytical data of **1** and **17** corresponded well with that in the literature.[@cit12a],[@cit12c]

![Formal synthesis of catharanthine (**3**) and the total synthesis of ibogamine (**1**). Reagents and conditions: (a) CeCl~3~ (2.5 equiv.), EtMgBr (2.0 equiv.), THF, 0.5 h, 72%; (b) ^*t*^BuOK (3.0 equiv.), Ph~3~PEtBr (3.0 equiv.), THF, 2 h, 92%; (c) H~2~, Pd/C (2.0 equiv.), MeOH, 2 h, 97%; (d) PhSiH~3~ (2.5 equiv.), Fe(acac)~3~ (0.8 equiv.), TBHP (1.5 equiv.), EtOH, 60 °C, 6 h; **19**, 34%; **1**, 26%; (e) ^*t*^BuOK (2.5 equiv.), TosMIC (1.3 equiv.), EtOH (1.7 equiv.), DME, 12 h; **20**, 25%; **21**, 54%.](c6sc00932h-s2){#sch2}

Encouraged by the completion of (+)-ibogamine (**1**), we moved towards the synthetic study of the *iboga* alkaloids with the methoxycarbonyl group at C16 ([Scheme 3](#sch3){ref-type="fig"}). The amide **13b** was prepared from the known compound **11b** with excellent enantiopurity[@cit18] following the same procedures depicted in [Scheme 1](#sch1){ref-type="fig"}, while the undesired diastereomeric amide could also be converted to **13b** readily (see ESI[†](#fn1){ref-type="fn"} for details). The selective reduction of the amide carbonyl group in **13b** subsequently afforded the tertiary amine **10b**.[@cit31] We fortunately isolated a trace amount of the rearranged product **6b** after the work-up of the gold-catalyzed oxidation reaction of **10b**, indicating that the \[1,2\]-shift was quite facile in the presence of the C16 methoxycarbonyl group. Therefore, the gold-catalyzed oxidation was followed by the addition of a saturated aqueous solution of sodium bicarbonate and excess triethylamine to promote the cyclization and rearrangement. Gratifyingly, this one-pot procedure afforded ketone **6b** in 51% yield from **10b** under mild reaction conditions. The Wittig reaction of **6b** gave rise to **22**---a catharanthine isomer with an exocyclic *versus* endocyclic double bond. Hydrogenation of **22** afforded dihydrocatharanthine (**4**) in 79% yield. Interestingly, **22** differs from a known compound derived from catharanthine in the olefin geometry.[@cit32] Eventually, employing the conditions reported by Boger and coworkers,[@cit32a] we successfully made vinblastine (**5**) in 50% yield by coupling **22** with commercially available vindoline **23**.

![Syntheses of dihydrocatharanthine (**4**) and vinblastine (**5**). Reagents and conditions: (a) Boc~2~O (3.0 equiv.), TEA (1.1 equiv.), DMAP (0.2 equiv.), DCM, RT, 14 h, 87%; (b) LDA (1.2 equiv.), **12** (2.5 equiv.), THF, 12 h; (c) TFA (5.0 equiv.), DCM, 16 h, 33% over two steps; (d) trimethyloxonium tetrafluoroborate (2.5 equiv.), 2,6-di-*tert*-butylpyridine (3.5 equiv.), DCM, 12 h; then NaBH~4~ (0.5 equiv.), MeOH, 0.5 h, 87%; (e) PPh~3~AuNTf~2~ (5 mol%), **14** (2.0 equiv.), MsOH (2.1 equiv.), AgOTf (2 mol%), DCE, RT, 5 h; then NaHCO~3~ (sat.), TEA (3.0 equiv.), RT, 3 h, 51%; (f) ^*t*^BuOK (3.0 equiv.), Ph~3~PEtBr (3.0 equiv.), THF, 2 h, 83%; (g) H~2~, PtO~2~ (0.3 equiv.), MeOH, 15 h, 79%; (h) vindoline **23** (1.2 equiv.), HCl-CF~3~CH~2~OH, FeCl~3~ (5.0 equiv.), 2 h; Fe~2~(ox)~3~ (30 equiv.), O~2~; then NaBH~4~ (20 equiv.), 0 °C, 0.5 h, 50%.](c6sc00932h-s3){#sch3}

It is noteworthy that the chiral compound **6b**, which was prepared from [l]{.smallcaps}-tryptophan in 8 steps, would be a valuable synthetic intermediate towards vinblastine analogs. To illustrate this point, compounds **24** and **25**, vinblastine analogs differing only in the C20′ substituent, were readily prepared by employing the Wittig reaction of **6b** followed by biomimetic coupling ([Fig. 3](#fig3){ref-type="fig"}). We also prepared fluoroalkene **27** using reagent **26**,[@cit33] where the *E* configuration of the olefin was assigned by a NOESY experiment (see ESI[†](#fn1){ref-type="fn"} for details). Interestingly, the coupling of **27** with vindoline (**23**) afforded aldehyde **28** in 68% yield (see Fig. S1[†](#fn1){ref-type="fn"} for a proposed mechanism). The cytotoxicities of **24** and **25** were measured in the HCT116 cell line using vinblastine (**5**) as a positive control. Our data indicated that **24** was over 100-fold less active than vinblastine, and that **25** was even less active than **24**. Based on a 40-step total synthesis, Fukuyama\'s group has reported inactive vinblastine analogs with C20′ acetylene functionalities that differ significantly in size and shape with the ethyl group of the natural product.[@cit34] Herein we showed that even a subtle change---with the C20′ alkyl substituent length extended for one (**24**) or two more carbons (**25**)---was enough to dramatically decrease the potency. This could be rationalized by the X-ray crystallographic analysis of the vinblastine--tubulin interactions, in which the C20′ ethyl substituent of vinblastine is embedded in a hydrophobic binding site.[@cit35] Interestingly, the aldehyde analog of vinblastine, compound **28**, almost lost the ability to inhibit the growth of HCT116 cells. However, compound **29**, obtained by the condensation of **28** with hydrazine, showed decent cytotoxicity (IC~50~ = 959 nM). This observation implies the necessity of a hydrogen bond donor around the C20′ position,[@cit36] although further investigation is needed to provide more insight into the hydrazone analog.

![Synthesis of vinblastine analogs and their cell growth inhibitory activity.](c6sc00932h-f3){#fig3}

Conclusions
===========

In summary, we have accomplished a unique and general route for the enantioselective synthesis of *iboga* alkaloids by developing a Stevens rearrangement through secondary amine catalysis and an oxidation/cyclization/rearrangement tandem sequence. The precise mechanism of the rearrangement remains to be investigated to identify whether a radical or an ionic intermediate is involved. Nonetheless, both reactions have the potential to be applied in the synthesis of a myriad of complex alkaloids. This study nicely exemplifies the total synthesis of complex natural products serving as not only a driving force for advancing the synthetic methodology but also as an important source for providing analogs. Furthermore, this practical approach to modify *iboga* alkaloids and vinblastine paves the way for studies into their pronounced pharmacological properties using state-of-the-art chemical biology technologies, which are underway in our group and will be reported in due course.
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